# Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

> **NCT03344419** · PHASE3 · SUSPENDED · sponsor: **New York State Psychiatric Institute** · enrollment: 150 (estimated)

## Conditions studied

- Cocaine Use Disorder

## Interventions

- **DRUG:** CI-581a
- **DRUG:** CI-581b
- **BEHAVIORAL:** Motivational Enhancement Therapy (MET)
- **BEHAVIORAL:** Mindfulness Based Relapse Prevention

## Key facts

- **NCT ID:** NCT03344419
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-10-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Funding
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344419, "Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03344419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*